Adoptive immunotherapy of tumours using cytokines to promote an anti-tumour response mounted by lymphocytes, macrophages and killer cells has attracted a great deal of attention in recent years (Colombo and Forni, 1994) . Much of this effort has been directed at interleukin 2 (IL-2). When used alone for this purpose it is effective for only a few tumour types and carries risks of severe toxic reactions (Bukowski et al., 1993) . Other members of the interleukin family also hold much promise, given the known interactions amongst the various cytokines (Jansen et al., 1990; Colombo and Forni, 1994) . Interleukin 4 (IL-4), the product of a subset of T lymphocytes (Th2), was initially believed to be a B-cell growth factor but is now known to have potent regulatory effects on haemopoietic cells of various lineages and regulates many of the effects of IL-2 (Jansen et Paul, 1991; Isakson, 1992; Paul and Seder, 1994) . Therefore, there is much enthusiasm about potential uses of IL-4 in this field (Lotze et al., 1990; Costello et al., 1993; Tepper et al., 1993) , especially since it potentiates the anti-proliferative effects of tumour necrosis factor a and interferon y on neoplastic cell lines, may itself have such effects and is tumoricidal in murine models (Totpal et al., 1991; Redmond et al., 1992; Topp et al., 1993) .
IL-4 mediates its biological effects by binding to a specific receptor present on the surface of target cells, which is a member of the haematopoietin receptor family (Keegan and Pierce, 1994) . The IL-4 receptor (IL-4R), which comprises the IL-4 binding component (CD124) together with the common y-chain (yc) is expressed by B and T lymphocytes, macrophages and mast cells (Jansen et al., 1990; Russel et al., 1993) . Increasingly however its presence is being reported on non-haemopoietic cells such as cell lines derived from melanoma and various epithelial tumours (Morisaki et al., 1992; Toi et al., 1992; Obiri et al., 1993 Obiri et al., , 1994 .
The monoclonal antibody (MAb) MR6 was raised against human thymic cortical epithelial cells but was also found to show weaker reactions with lymphocytes, dendritic cells, macrophages and some non-thymic epithelia (DeMaagd et al., 1985; von Gaudecker et al., 1995) . Subsequent investigations showed that MAb MR6 detects a 200 kDa glycoprotein (gp200-MR6) and that addition of the MAb to in vitro assays blocks IL-4-induced proliferation of cloned T cells and the IL-4-dependent switch to IgE in allergenstimulated B cells, and may inhibit the development and expansion of IL4-secreting 'Th2' T helper cells; these data indicate that gp200-MR6 is functionally associated with the IL-4R, although MAb MR6 does not interfere with the binding of IL-4 to the CD124 ligand-binding chain of the receptor (Larche et al., 1988; Mat et al., 1990; Imami et al., 1994) .
We have previously used MAb MR6 to demonstrate the presence of gp200-MR6 in surgically resected breast, pulmonary and colorectal carcinomas (Mat et al., 1990; Tungekar et al., 1991; Kaklamanis et al., 1992) . However, not all tumours were gp200-MR6 positive, and a subsequent detailed analysis of breast tumours showed that loss of this molecule was associated with higher grade tumours (Mat et al., 1993 ). These observations not only suggest that gp200-MR6 expression may be useful in prognostic evaluation, but also raise the possibility of direct effects of IL-4 on epithelial tumours in addition to its recognised immunoregulatory influences on the cells infiltrating the tumour stroma.
Intravesical immunotherapy with BCG is a well-established method of treatment for superficial transitional cell carcinomas of the bladder (Ozen, 1993) . For advanced forms of these tumours arterial infusion of recombinant interleukin 2 (rIL-2) with lymphokine-activated killer cells has been tried with mixed results (Hermann et al., 1992) . The application of IL-4 in this area is likely to be explored in future in view of the synergistic effects it shares with other cytokines. For this reason a study of IL-4R and gp200-MR6 expression in transitional cell carcinomas of bladder is particularly relevant.
We have therefore used MAb MR6 to investigate the expression of gp200-MR6 in a series of 28 resected urothelial bladder carcinomas of various grades and stages. Our data reveal that it is universally expressed by these tumours and by non-neoplastic urothelium. In contrast, the tumours were heterogeneous in their expression of epidermal growth factor receptors (EGFRs) and mutant p53, and exhibited a broad range of proliferative grades as determined by Ki67 staining. (International Union Against Cancer, 1987) . The tumours were all transitional cell carcinomas; of these, 12 were grade 2, and 16 grade 3. Depths of invasion and grades are summarised in Table I . Twelve specimens of non-neoplastic urothelium were available as controls: five of these were excised with tumours and the rest obtained at cystoscopic examination that turned out to be substantially normal.
The primary MAb antibodies used are indicated in Table  II . All are murine IgGI reagents except EGFR1 which belongs to the IgG 2 class. Staining with Ki67 was carried out to study the proliferation rates and to assess the general state of preservation of antigens since the Ki67 antigen is highly sensitive to degradation.
Immunohistochemical staining was performed using the alkaline phosphatase-anti-alkaline phosphatase procedure as described previously (Cordell et al., 1984) . No staining was observed when the primary antibody was omitted or when it was replaced by an irrelevant isotype-matched monoclonal antibody (Figure 1 ).
Results
A total of 28/28 transitional cell carcinomas of the bladder expressed the gp200-MR6. Nearly all the cells within these tumours stained with the MAb MR6, although the intensity of the staining varied from moderate to strong with different areas of each tumour (Figure 2 ). The staining was mostly concentrated on the cell surfaces and was more intense at the periphery of tumour masses than at their centre. However the intensity of immunoreactivity showed no significant relationship to the grades or stages of the tumours (Figure 3) . The results of immunostaining for EGFR and p53 positivity are summarised in Table III. EGFR and p53 positivity were seen in 20/28 and 14/28 cases respectively. The Ki67 positivity rate of the individual tumours ranged from 5% to 95%.
In all the control specimens, non-neoplastic urothelium showed labelling with MAb MR6, with more intense staining of the basal layers and hyperplastic von Brunn's nests ( Figure  4) . The lymphoid cells infiltrating the tumour stroma were strongly labelled with MAB MR6 (Figure 3 ). Non-invasive, G2 (n = 11) pTa (n = 11) papillary (n = 11) Tunica propria (n=9) G2 (n=5), G3 (n=4) pTI ( (Ozen, 1993) . Treatment of advanced carcinomas of these types with infusions of rIL-2 with lymphokine-activated killer (LAK) cells has not had much success and also has toxic side-effects (Hermann et al., 1992; Ozen, 1993) . Recombinant IL-4 (rIL-4) enhances the proliferation of tumour infiltrating lymphocytes (TILs) and macrophages induced by IL-2 in bladder carcinomas (Kawakami et al., 1993) , and therefore appears to be a logical addition to IL-2 in treatment of these tumours.
Our demonstration that gp200-MR6, which is functionally associated with the IL-4R, is expressed on neoplastic urothelium and other epithelia raises important questions about such possible therapeutic applications of IL-4 (Larche et al., 1988; Mat et al., 1990; Tungekar et al., 1991; Kaklamanis et al., 1992; Mat et al., 1993; Imami et al., 1994 (Totpal et al., 1991; Morisaki et al., 1992 Morisaki et al., , 1994 Toi et al., 1992; Obiri et al., 1993 Obiri et al., , 1994 . Clinical studies of certain subsets of breast cancers suggest that cytokines released from host cells infiltrating tumour stroma may act in a paracrine fashion to promote growth of neoplastic cells and that cytotoxic therapy is beneficial because of its immunosuppressive effects (Stewart and Tsai, 1993) . The expression of gp200-MR6 by nonneoplastic urothelium as well as all the urothelial carcinomas may point to a fundamental physiological role for in homeostasis of this tissue that is retained in its neoplastic transformation. The finding that all bladder carcinomas express gp200-MR6 is in contrast to the selective pattern of expression of this molecule in tumours of lung, breast, colon and rectum (Mat et al., 1990 (Mat et al., , 1993 Tungekar et al., 1991; Kaklamanis et al., 1992) . Thus approximately 35% of all non-small-cell carcinomas of the lung and 30% of breast carcinomas were positive for gp200-MR6, whereas all colorectal adenomas and 90% of carcinomas expressed the antigen (Mat et al., 1990 (Mat et al., , 1993 Tungekar et al., 1991; Kaklamanis et al., 1992) . Moreover, loss of gp200-MR6 in carcinoma of the breast has been shown to be associated with increased malignancy (Mat et al., 1993) . The retention of gp200-MR6 expression by all transitional bladder cell carcinomas may give the impression that the cohort of tumours in the present study was biologically homogeneous. That this is unlikely to be the case is illustrated by the obvious heterogeneity of the tumours in terms of known markers of biological behaviour such as grade, stage, proliferative activity determined by Ki67 labelling, and expression of EGFR and mutant p53. These observations indicate that IL-4 may play a role in maintaining the integrity of transitional epithelium even in its neoplastic state and that gp200-MR6 expression is unlikely to be useful in predicting the biological behaviour of bladder tumours. Moreover, while it should be possible to use antibodies such as MR6 with radioisotopic tags for visualisation of primary and metastatic disease in urothelial carcinomas, as previously shown for the lung, the presence of IL-4R on normal epithelia would argue against the use of chimaeric toxin -IL-4 conjugates to target IL-4R positive tumours because of the risks of epithelial damage (Al Jabaari et al., 1989; Lakkis et al., 1991; Debinski et al., 1993) .
In conclusion, this study, by demonstrating gp200-MR6 on normal and neoplastic urothelium, has further extended the list of target cells that may be susceptible to the influence of and has raised new issues regarding the application of this versatile cytokine in adoptive immunotherapy of tumours. It has also highlighted the possible physiological influence of IL-4 on epithelia and emphasises the importance of studying the expression of receptors in surgical biopsy material in addition to the in vitro studies performed on cell lines and in animal models.
